Labcorp won FDA clearance for its PGDx elio tissue complete CDx, a companion diagnostic for advanced melanoma that detects BRAF V600E and V600K variants in tumor tissue; the company said the test showed a 94.4% clinical pass rate among melanoma cases. The clearance gives clinicians another FDA-cleared option to identify patients who may be eligible for targeted BRAF- and BRAF/MEK-directed therapies.

Why It Matters To Oncology

• Advanced melanoma is an aggressive malignant neoplasm where rapid molecular stratification can directly shape treatment selection.

• The test is intended to identify tumors with BRAF V600E or V600K alterations, which can open the door to FDA-approved targeted options including dabrafenib, vemurafenib, and combination regimens with MEK inhibitors.

• Because the assay is kit-based and can be run by hospitals and health systems, it may broaden local access to companion testing and reduce delays tied to send-out workflows.

The Financials

• Labcorp did not disclose pricing or revenue expectations tied to the FDA clearance.

• Commercially, the approval strengthens Labcorp's precision oncology diagnostics portfolio in a competitive BRAF testing market that includes Caris, Foundation Medicine, bioMérieux, and Roche.

• For drug developers, broader testing access could support uptake of already-approved BRAF and BRAF/MEK therapies by helping identify eligible patients faster.

What They're Saying

• "Advanced melanoma is an extremely aggressive and life-threatening cancer, but targeted treatments are offering real hope for patients," said Shakti Ramkissoon, Labcorp's vice president of oncology.

• Ramkissoon added that the new test "improves access to these therapies by allowing clinicians to confirm which patients may be eligible for and can start receiving those treatments as soon as possible."

What's Next

• Clinicians will be watching how quickly the assay is adopted across hospital and health-system laboratories.

• Another key question is whether expanded in-house access to BRAF testing shortens time to treatment initiation for patients with advanced melanoma.

• In drug discovery and development, wider companion diagnostic availability may help refine patient identification for future melanoma trials and lifecycle management around targeted agents.